睿知中国医院研究地图
候选清单

上海

Child Health Hospital

在本站收录的 61 种疾病中,这家医院列在其中 2 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

Child Health Hospital的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 乳腺癌Breast cancer26 篇牵头论文
  2. 先天性心脏病Congenital heart disease8 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝细胞癌、胃癌、肺癌、胰腺癌、胶质瘤、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、脊柱侧弯、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 26 篇,占 0.1%。

牵头论文
26
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 3320222023: 4420232024: 3320242025: 11112025

上海有 19 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的乳腺癌开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

医院名称从作者地址自动识别,尚未人工核对。

牵头的论文26
  1. Individualized dosing strategies in breast cancer chemotherapy: Evidence for therapeutic drug monitoring-guided docetaxel treatment.2026European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical SciencesRCT
  2. Circ_0006174 Drives Triple Negative Breast Cancer Progression and Immune Escape Through Regulating miR-3139/PD-L1 Axis.2026The Kaohsiung journal of medical sciences免费全文
  3. Trends and projections of global gynaecological cancer burden: age-period-cohort insights from Global Burden of Disease 2021.2025BMC women's health免费全文
  4. Fertility preservation in young breast cancer patients: A nationwide survey on knowledge, attitudes, and practices among breast surgical healthcare providers in China.2025Breast (Edinburgh, Scotland)免费全文
  5. The necessity of adjuvant chemotherapy in young patients with T1N0M0 breast cancer: a population-based study.2025Clinical and experimental medicine免费全文
  6. The Efficacy Research of Prophylactic PEG-rhG-CSF in Preventing Neutropenia in Early-Stage Breast Cancer Patients Treated With Docetaxel-Based Chemotherapy: A Retrospective Analysis.2025Clinical therapeutics
  7. Clinical and Prognostic Implications of an Alternative Splicing-related Risk Model Based on TP53 Status in Breast Cancer.2025Current pharmaceutical biotechnology
  8. Comparative analysis of the clinicopathological features and prognostic implications of invasive breast carcinoma of nonspecial type exhibiting HER2-low and HER2-zero expressions.2025Journal of cancer research and therapeutics
  9. FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination.2025Journal of experimental & clinical cancer research : CR免费全文
  10. Identification of Molecular Subtypes and Prognostic Features for Triple-Negative Breast Cancer Based on Golgi Apparatus-Related Gene Signature.2025Oncology research免费全文
  11. Knowledge, attitude, and practice toward genetic testing in breast cancer patients in China.2025PloS one免费全文
  12. CircTNFRSF19 facilitates triple negative breast cancer cell growth by regulating N6-methyladenosine modification of B3GNT5: Medical biological image simulation.2025SLAS technology
  13. Long term efficacy of adjuvant chemotherapy in elderly patients with early stage breast cancer assessed through SEER database analysis.2025Scientific reports免费全文
  14. Natural compound Byakangelicin suppresses breast tumor growth and motility by regulating SHP-1/JAK2/STAT3 signal pathway.2024Biochemical and biophysical research communications
  15. Knowledge and Awareness Toward Menopausal Hormone Therapy in a Fourth-Tier City of China.2024Medical science monitor : international medical journal of experimental and clinical research免费全文
  16. Transforming growth factor-induced gene TGFBI is correlated with the prognosis and immune infiltrations of breast cancer.2024World journal of surgical oncology免费全文
  17. The heterogeneity of tumour immune microenvironment revealing the CRABP2/CD69 signature discriminates distinct clinical outcomes in breast cancer.2023British journal of cancer免费全文
  18. Epigenetic regulation of LINC01270 in breast cancer progression by mediating LAMA2 promoter methylation and MAPK signaling pathway.2023Cell biology and toxicology
  19. Clinicopathological features and prognoses of very young patients (≤35 years) with breast cancer: a retrospective population-based study in China.2023Chinese medical journal免费全文
  20. Reconceptualizing the clinicopathological features, locoregional therapy and prognostic factors of occult breast cancer in the era of molecular subtyping.2023Women & health
  21. Development of a Cancer-Associated Fibroblast-Related Prognostic Model in Breast Cancer via Bulk and Single-Cell RNA Sequencing.2022BioMed research international免费全文
  22. Actin-binding Rho activating C-terminal like (ABRACL) transcriptionally regulated by MYB proto-oncogene like 2 (MYBL2) promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of breast cancer cells.2022Bioengineered免费全文
  23. Artificial intelligence breast ultrasound and handheld ultrasound in the BI-RADS categorization of breast lesions: A pilot head to head comparison study in screening program.2022Frontiers in public health免费全文
  24. Inhibin β-A (INHBA) induces epithelial-mesenchymal transition and accelerates the motility of breast cancer cells by activating the TGF-β signaling pathway.2021Bioengineered免费全文
  25. Comparative analysis of clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast and invasive ductal carcinoma: results from SEER database.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  26. AC016405.3 functions as an oncogenic long non-coding RNA by regulating ERBB3 via sponging miR-22-3p in breast cancer.2021Journal of clinical laboratory analysis免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Study of Prediction of Ovarian Reserve in Yong Breast Cancer Patients Treated With Chemotherapy已完成NCT04767607牵头方2020-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 3320232024: 1120242025: 442025

上海有 19 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录

医院名称从作者地址自动识别,尚未人工核对。

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

Child Health Hospital

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
IPMCH; International Peace Maternity & Child Health Hospital

提出更正下载数据